Reason Behind Today’s Notable Altcoin Surge Is Now Clear: Developers Will Only Get Paid If the Price Increases Fivefold
Everythingempty, one of the co-founders of the Virtuals (VIRTUAL) team, published an early-stage proposal on the X platform, bringing forward the allocation of performance-based ecosystem funding to Virgen Labs.
This proposal, approved in July, includes a rewards plan based on price targets.
According to the proposal, if the VIRTUAL token price reaches $10, $20, and $40, respectively, it will trigger a token allocation equivalent to 2% of the total supply to the Virgen Labs team. If all targets are met, the team will earn a total reward of 6% (60 million VIRTUAL tokens).
Each phase will be verified using 30-day time-weighted average price (TWAP) data from the Binance spot market and a daily trading volume exceeding $10 million. Once the target is reached, the tokens will be gradually unlocked via smart contracts at a weekly rate of 0.013% over 36 months.
The proposal states that no new tokens will be minted. However, if all targets are met, the share of the DAO treasury will decrease from 34% to 28%. This will only apply if the VIRTUAL price reaches $40.
According to Coingecko data, the current price of VIRTUAL is at $1.83 and the token has gained 33.9% in the last 24 hours.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate
